AUTHOR=Yang Jing , Jiang Wenwen , Deng Jianqing , Liu Min , Xue Ya , Bao Jizhang , Jia Tingting , Hu Qi , Zhang Lichao 

TITLE=Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report

JOURNAL=Frontiers in Medicine

VOLUME=Volume 12 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1541235

DOI=10.3389/fmed.2025.1541235

ISSN=2296-858X

ABSTRACT=VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But its application in patients with severe liver dysfunction has not been evaluated. Here, we report a case in which a patient with aplastic anemia and liver impairment (recovery phase of acute liver failure) was infected with SARS-CoV-2. Based on clinical trials and pharmacokinetic analysis about VV116, we initiated a reduced dose of 300 mg every 12 h on day 1, 200 mg every 12 h on days 2–5 for antiviral therapy. Finally, the patient’s viral load rapidly dropped to an undetected level, and no drug-related adverse effects were observed.